Literature DB >> 19668614

Human growth hormone therapy in Prader-Willi syndrome.

.   

Abstract

Entities:  

Year:  2005        PMID： 19668614      PMCID： PMC2722526     

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


× No keyword cloud information.
  6 in total

1.  Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee.

Authors:  Thomas A Wilson; Susan R Rose; Pinchas Cohen; Alan D Rogol; Philippe Backeljauw; Rosalind Brown; Dana S Hardin; Stephen F Kemp; Margaret Lawson; Sally Radovick; Stephen M Rosenthal; Lawrence Silverman; Phyllis Speiser
Journal:  J Pediatr       Date:  2003-10       Impact factor: 4.406

2.  Growth hormone therapy in children in Canada: what have we learned in the past decade from an unlimited supply of growth hormone?

Authors:  H Dean
Journal:  Clin Invest Med       Date:  1999-04       Impact factor: 0.825

3.  Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome.

Authors:  Aaron L Carrel; Victoria Moerchen; Susan E Myers; M Tracy Bekx; Barbara Y Whitman; David B Allen
Journal:  J Pediatr       Date:  2004-12       Impact factor: 4.406

Review 4.  Sleep and breathing in Prader-Willi syndrome.

Authors:  Gillian M Nixon; Robert T Brouillette
Journal:  Pediatr Pulmonol       Date:  2002-09

5.  Prader-Willi syndrome: causes of death in an international series of 27 cases.

Authors:  Constance Th R M Schrander-Stumpel; Leopold M G Curfs; Prapto Sastrowijoto; Suzanne B Cassidy; Jaap J P Schrander; Jean-Pierre Fryns
Journal:  Am J Med Genet A       Date:  2004-02-01       Impact factor: 2.802

Review 6.  Sudden death in growth hormone-treated children with Prader-Willi syndrome.

Authors:  Guy Van Vliet; Cheri L Deal; Patricia A Crock; Yves Robitaille; Luc L Oligny
Journal:  J Pediatr       Date:  2004-01       Impact factor: 4.406
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.